AI Article Synopsis
- - In 2023, key studies in reproductive endocrinology focused on fertility preservation for men with Klinefelter's syndrome, evaluating testosterone replacement therapy's cardiovascular safety, and introducing fezolinetant as a new treatment for menopause symptoms.
- - Updated European guidelines on adrenal incidentalomas are set to significantly change clinical practice in this area.
- - New data revealed that approximately 1 in 1000 individuals have pituitary adenomas, and a large study in Britain refined the treatment options for hyperthyroidism by assessing their benefit-risk profiles.
Article Abstract
This overview provides a selection of studies published in 2023 with an impact on clinical practice. In reproductive endocrinology, important studies have addressed fertility preservation in men with Klinefelter's syndrome, the cardiovascular safety of testosterone replacement therapy, and a novel therapy, fezolinetant, for vasomotor symptoms of menopause. The updated European recommendations concerning adrenal incidentalomas will considerably modify current clinical practice. Based on a solid epidemiological work, the prevalence of pituitary adenomas has been confirmed to affect about 1 per 1000 individuals. Finally, a large British study allows to refine the benefit-risk profile of the three options available for the treatment of hyperthyroidism.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.53738/REVMED.2024.20.856-7.36 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!